SAMJIN PHARMACEUTICAL CO.,LTD: debt-to-equity, ROE and more
KOSPI, Legal name SAMJIN PHARMACEUTICAL CO.,LTD
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 62.0%
- Equity ratio
- 61.7%
- ROE
- 8.3%
- Op. margin
- 8.7%
- Rev. growth
- 0.3%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩800 | 41.9% |
| 2024 | ₩800 | 25.0% |
| 2023 | ₩800 | 54.1% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 42.0% | 70.4% | 12.1% | 13.6% | n/a |
| FY2022 consolidated | 47.4% | 67.9% | 7.9% | 8.5% | 9.6% |
| FY2023 separate | 58.2% | 63.2% | 7.1% | 7.0% | 6.6% |
| FY2024 separate | 62.5% | 61.5% | 15.0% | 10.3% | 5.6% |
| FY2025 separate | 62.0% | 61.7% | 8.3% | 8.7% | 0.3% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩250.1B | ₩274.0B | ₩292.1B | ₩308.3B | ₩309.1B |
| Operating profit | ₩33.9B | ₩23.2B | ₩20.5B | ₩31.6B | ₩26.8B |
| Pre-tax income | ₩34.9B | ₩25.2B | ₩15.6B | ₩43.6B | ₩22.1B |
| Net income | ₩28.4B | ₩21.9B | ₩18.9B | ₩39.2B | ₩24.2B |
| Total assets | ₩332.5B | ₩406.6B | ₩419.9B | ₩425.2B | ₩470.5B |
| Total liabilities | ₩98.3B | ₩130.7B | ₩154.5B | ₩163.5B | ₩180.1B |
| Total equity | ₩234.2B | ₩275.9B | ₩265.4B | ₩261.7B | ₩290.4B |
| Paid-in capital | ₩13.9B | ₩13.9B | 0 | 0 | ₩13.9B |
| Debt/equity (source value) | 42.0% | 47.4% | 58.2% | 62.5% | 62.0% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 1968-04-18
- Listed
- 88/06/18
- Employees
- 819
- Auditor
- 한울회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110088652
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 삼진제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.